Singapore’s manufacturing output rose in September 2025 despite US tariffs on pharmaceuticals. SMU Lee Kong Chian Professor of Operations Management Shantanu Bhattacharya said that Asia will continue to have an edge in active pharmaceutical ingredient (API) manufacturing, which is not cost-effective in the US. Prof Bhattacharya attributed this to labour cost, which is much higher in the US compared to Asia.
